Adele K. Fielding

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications

What next after the first BITE of the CD19 cherry in ALL?

What next after the first BITE of the CD19 cherry in ALL?

Journal: Blood
Published: April 23, 2026

COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.

COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.

Journal: British journal of haematology
Published: July 17, 2025

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.

Journal: Leukemia
Published: January 28, 2025

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.

Journal: Blood
Published: February 14, 2024

Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.

Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.

Journal: American journal of hematology
Published: January 04, 2024

Management of ALL in adults: 2024 ELN recommendations from a European expert panel.

Management of ALL in adults: 2024 ELN recommendations from a European expert panel.

Journal: Blood
Published: December 19, 2023

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts.

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts.

Journal: Blood advances
Published: October 30, 2023

A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.

A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.

Journal: Blood advances
Published: September 12, 2023

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia.

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia.

Journal: HemaSphere
Published: August 11, 2023

Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform.

Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform.

Journal: Leukemia
Published: July 21, 2023

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.

Journal: Blood
Published: July 11, 2023

ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.

ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.

Journal: BMJ open
Published: June 01, 2023
Showing 1-12 of 92

Last Updated: 09/26/2026